anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide a decolorizing cosmetic or dermatolgic compsn. containing di- or tri-caffeoylquinic acid. CONSTITUTION: At least one or mixture of di- and tricaffeoylquinic acid expressed by formula I is incorporated in an effective amt. in a decolorizing effect into a proper cosmetic or dermatological carrier. In the formula I, R1 to R4 are each H or expressed by formula II, however, at least two of R1 to R4 or at the max. three of them are expressed by formula II except that R1 and R4 are the same as formula II and that R2 and R3 are the same as H. The compounding amt. of the compd. of formula I is 0.01 to 15 wt.% of the sum weight of the compsn., and preferably 0.1 to 8 wt.%. The comspn. is preferably prepared in a lotion, cream, emulsion, gel, masking agent, or particle dispersant with ionic lipid (liposome) and/or nonionic lipid formed.
Seventeen patients will receive treatment using the infrared wavelength (970 nm) to provide biosstimulation. plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
BACKGROUND: The number of donors from donation after circulatory determination of death (DCDD) has increased by at least 4-fold over the past decade. This study evaluated the association between the antecedent cardiac arrest status of controlled DCDD donors and the risk of delayed graft function (DGF).
METHODS: Using data from the Australia and New Zealand Dialysis and Transplant, the associations between antecedent cardiac arrest status of DCDD donors before withdrawal of cardiorespiratory support, DGF, posttransplant estimated glomerular filtration rate (eGFR), and allograft loss were examined using adjusted logistic, linear mixed modeling, and cox regression, respectively. Among donors who experienced cardiac arrest, we evaluated the association between duration and unwitnessed status of arrest and DGF.
RESULTS: A total of 1173 kidney transplant recipients received DCDD kidneys from 646 donors in Australia between 2014 and 2019. Of these, 335 DCDD had antecedent cardiac arrest. Compared with recipients of kidneys from donors without antecedent cardiac arrest, the adjusted odds ratio (95% confidence interval) for DGF was 0.85 (0.65-1.11) among those with kidneys from donors with cardiac arrest. There was no association between antecedent cardiac arrest and posttransplant eGFR or allograft loss. The duration of cardiac arrest and unwitnessed status were not associated with DGF.
CONCLUSIONS: This focused analysis in an Australian population showed that the allograft outcomes were similar whether DCDD donors had experienced a prior cardiac arrest, with no associations between duration or unwitnessed status of arrest and risk of DGF. This study thus provides important reassurance to transplant programs and the patients they counsel, to accept kidneys from donors through the DCDD pathway irrespective of a prior cardiac arrest.
An operating table control apparatus is disclosed. The operating table control apparatus has a remote control device, a first transmitting-receiving device that is mountable to the remote control device, and a second transmitting-receiving device that is mountable to a first operating table. The first transmitting-receiving device is configured to transmit a request command to the second transmitting-receiving device. After receiving the request command from the first transmitting-receiving device, the second transmitting-receiving device is configured to transmit a device address of the first operating table to the first transmitting-receiving device. The first transmitting-receiving device is configured to adopt the device address received from the second transmitting-receiving device, establishing a paired operating state between the first transmitting-receiving device and the second transmitting-receiving device. The first transmitting-receiving device is configured to transmit both a control command and the device address to the second transmitting-receiving device.
Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
The process comprises reaction of an amide of formula (II) with a chlorinated deriv. in an organic solvent and e in the presence of a tert. amine at 50-150 deg.C. Following the reaction, the solvent and the excess chlorinated deriv. are removed by vacuum distillation or filtration. Deriv. can be phosphorus pentachloride and the solvent can be benzene, etc.
Aggressive triple-negative breast cancer (TNBC) still lacks approved targeted therapies, requiring more exploration of its underlying mechanisms. Previous studies have suggested a potential role of SAT1 (Spermidine/Spermine N1-acetyltransferase 1) in cancer, which needs to be further elucidated in breast cancer. In this study, highly expressed SAT1 in TNBC signified worse patient prognoses. And SAT1 knockdown effectively inhibited the proliferation and migration abilities of TNBC cells in vitro and in vivo. In terms of mechanism, the transcription factor JUN enhanced SAT1 transcriptional activity by binding to its promoter region. Then, SAT1 protein in the cytoplasm engaged in directly binding with YBX1 for sustaining YBX1 protein stability via deubiquitylation mediated by the E3 ligase HERC5. Further, SAT1 was found to suppress autophagy remarkably via stabilization of mTOR mRNA with the accumulation of YBX1-mediated methyl-5-cytosine (m5C) modification. These findings proved that SAT1 drives TNBC progression through the SAT1/YBX1/mTOR axis, which may provide a potential candidate for targeted therapy in advanced TNBC.
Surgery for severe aortic stenosis (AS) prior to symptom onset is controversial. Conventionally changes in valve area and gradient are used to time intervention but myocardial changes may be more predictive of surgical need. This study aims to elucidate the role of diffuse myocardial fibrosis as a prognostic marker, implementing a novel, non-invasive technique to measure it.

AS is the most common valvular heart condition in the United Kingdom and the Western world. Its prevalence rises with age - about 3% aged over 75 have severe AS. During a period of progressive valve narrowing, the left ventricle (LV) adapts to the increased pressure with increasing concentric muscle hypertrophy. However, eventually this remodelling becomes maladaptive and the LV less compliant, leading to symptoms (breathlessness, chest pain, and loss of consciousness). This heralds a significant increase in morbidity and mortality. Consequently aortic valve replacement (AVR) in symptomatic patients is a Class I indication. In most asymptomatic patients however, prophylactic surgery is controversial: the risk of surgery is thought to be greater than watchful waiting, although there is no randomised data to support this approach. Conversely, diffuse myocardial fibrosis is thought to play a key role in functional deterioration, symptom development and possibly outcome in AS. Unfortunately, assessment of AS severity, including hemodynamic parameters such as peak velocity and mean gradient, poorly predict symptom development and/or optimal timing of surgery.

A non-invasive technique to quantify diffuse myocardial fibrosis against the gold standard of myocardial biopsy has been developed and validated in patients with AS: Cardiovascular magnetic resonance (CMR) with T1 mapping uses the extracellular tracer gadolinium to measure the extracellular volume (ECV), which closely reflects the degree of diffuse fibrosis. An important observation in a previous cohort (Flett et al European Heart Journal Cardiovascular Imaging 2012) was the fate of patients with severe fibrosis: they were more symptomatic at baseline, improved the most post-operatively and yet carried a trend towards increased mortality at six months. To unravel this, this study aims to track diffuse fibrosis in the RELIEF-AS study with a larger cohort (n=150) and for longer (12 months) to understand how to use diffuse fibrosis as a prognostic marker.
This is a multicenter, open-label, single-arm, phase II Study to Evaluate the safety, tolerability, pharmacokinetics and preliminary Efficacy of intermittent oral dosing of CM082 tablets in Chinese patients with wAMD. The study will be performed in two different parts, dose-escalation phase (Part 1) and dose-expansion phase (Part 2). Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. There are two dose levels, 25mg BID and 50mg BID. In part 1, the starting dose of 25mg BID(n=8) will be increased by 100% to the maximum dose of 50mg BID(n=8) if the number of patients who experience dose-limiting toxicities is less than 2 during the first cycle. In part 2, based on the relevant data from the dose escalation study, an expanded enrollment study was conducted at a safe and effective dose.Per dose group will enroll 12-24 patients. All patients will take CM082 until disease progression or unacceptable toxicity. The assessment of the safety and efficacy will be done every four weeks from 2nd-6th cycle and every 12 weeks after. Also, single/multiple dose pharmacokinetics in these patients will be studied.
The invention relates to a medicament for treating lymphedema and venous edema. The medicament is mainly prepared from the following raw material medicaments in part by weight: 20 to 40 parts of lightyellow sophora root, 5 to 15 parts of figwort root, 5 to 15 parts of root of red-rooted salvia and 5 to 15 parts of ginger. The invention also discloses application of the medicament for treating the lymphedema and the venous edema. The invention belongs to a Chinese medicinal compound preparation, and the compatibility meets the principle of monarch, minister, assistant and guide of Chinese medicaments. Pharmacodynamic experiments prove that the medicament can obviously reduce the lymphedema and the venous edema of patients, and prevent and treat skin tissue infection, hyperblastosis of skin and hypoderm and fibrosis complication. The lightyellow sophora root, the figwort root and the root red-rooted salvia in the medicament for treating the lymphedema and the venous edema have obvious synergistic effects; the ginger can reduce coldness of the medicaments; and fructus amomi has the effects of nourishing stomach. Therefore, the medicament reduces the side effects of stomach discomfort when improving curative effects. The medicament has small side effects, is suitable for long-term use, and is the safe and effective medicament for treating the lymphedema.
PROBLEM TO BE SOLVED: To provide a chitosan solution stable at near neutral and its dried product, these are widely applicable to the fields of cosmetics, foodstuff and the like. SOLUTION: The stable aqueous chitosan solution containing chitosan solubilized with use of an inorganic or organic acid, has pH of neutral, preferably pH 6 to 7, without including any excess acid practically, and is processed to a dried product thereof. The chitosan solution is deacidified to the extent of giving no acidic stimulation to the skin. A method of producing the aqueous chitosan solution is characterized by that chitosan is dissolved in an acid, then the excess acid is removed giving the near neutral stable aqueous chitosan solution by controlling a water content of the chitosan solution, after removing the excess acid, so that concentration of the chitosan may keep a constant value providing pH of near neutral. After removal of the excess acid, and chitosan is treated with an adsorbent.  The chitosan is dispersed in water and is dissolved by adding an inorganic or organic acid. The excess acid is removed by using a strong or weak basic anion exchange resin or chitosan derived from a natural product.
Participants with weight \< 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
Embodiments of present disclosure disclose method and system for generating a medical image based on a textual data in a medical report. For generation, a textual data from each of one or more medical reports of the patient is retrieved. The textual data comprises one or more medical events and corresponding one or more attributes associated with each of the one or more medical reports. Further, a matching score for each of plurality of reference images is computed based on the textual data, using a first machine learning model. Upon computing the matching score, one or more images are selected from the plurality of reference images based on the matching score associated with each of the plurality of reference images. The medical image for the patient is generated based on the one or more images and the textual data using a second machine learning model.
OBJECTIVE: Cancer-related fatigue (CRF) and fear of cancer recurrence (FCR) are two common concerns experienced by cancer survivors. However, the relationship between these two concerns is poorly understood, and whether CRF and FCR influence each other over time is unclear.
METHODS: Data were from a national, prospective, longitudinal study, the American Cancer Society's Study of Cancer Survivors-I (SCS-I). Surveys were completed by 1395 survivors of 10 different cancer types at three time-points, including assessment 1.3 years (T1), 2.2 years (T2) and 8.8 years (T3) following their cancer diagnosis. CRF was assessed using the fatigue-inertia subscale of the Profile of Mood States, and FCR by the FCR subscale of the Cancer Problems in Living Scale. Multiple group random intercepts cross-lagged panel models investigated prospective associations between CRF and FCR.
RESULTS: For younger participants (at or below median age of 55 years, n = 697), CRF at T1 and T2 marginally and significantly predicted FCR at T2 and T3, respectively, but no lagged effects of FCR on subsequent CRF were observed. Cross-lagged effects were not observed for survivors over 55 years of age.
CONCLUSION: Both CRF and FCR are debilitating side effects of cancer and its treatments. Given that CRF may be predictive of FCR, it possible that early detection and intervention for CRF could contribute to lowering FCR severity.
BACKGROUND: Morphine is the most used opioid for dyspnea, but other opioids such as oxycodone and fentanyl are increasingly used, and opioid switching to these is sometimes undertaken. No studies have verified the effectiveness of opioid switching for relief of dyspnea. We retrospectively investigated the effectiveness of opioid switching for dyspnea and its predictors.
METHODS: All patients with opioid switching for dyspnea during hospitalization at Komaki City Hospital from January 2019 to August 2022 were included. Opioid switching was defined as a change to another opioid, and the assessment period for evaluating the effectiveness and adverse events of opioid switching was set as 1 week. Patients with Numeric Rating Scale or Japanese version of the Support Team Assessment Schedule reduction for dyspnea of at least 1, or with clear improvement based on medical records, were considered valid. Mitigating factors for dyspnea were identified using logistic regression analysis.
RESULTS: Of the 976 patients with opioid switching, 57 patients had opioid switching for relief of dyspnea. Of these, opioid switching was effective in 21 patients (36.8%). In a multivariate analysis, older patients (odds ratio: 5.52, 95% CI: 1.50-20.20, P < 0.01), short prognosis for post-opioid switching (odds ratio: 0.20, 95% CI: 0.04-0.87, P = 0.03) and cachexia (odds ratio: 0.12, 95% CI: 0.02-0.64, P < 0.01) were significantly associated with opioid switching effects for dyspnea. There were no serious adverse events after opioid switching.
CONCLUSION: This study indicates that opioid switching for dyspnea may have some effect. Furthermore, opioid switching for dyspnea may be more effective in older patients and less effective in terminally ill patients or in those with cachexia.
HEMLIBRA restores the tenase cofactor activity of missing activated factor VIII (FVIIIa). Coagulation laboratory tests based on intrinsic clotting (i.e., aPTT) measure the total clotting time including time needed for activation of FVIII to FVIIIa by thrombin. Such intrinsic pathway-based tests will yield overly shortened clotting times with HEMLIBRA, which does not require activation by thrombin. The overly shortened intrinsic clotting time will then disturb all single-factor assays based on aPTT, such as the one-stage FVIII activity assay; however, single-factor assays utilizing chromogenic or immuno-based methods are unaffected by HEMLIBRA and may be used to monitor coagulation parameters during treatment, with specific considerations for FVIII chromogenic activity assays as described below.

Chromogenic FVIII activity tests may be manufactured with either human or bovine coagulation proteins. Assays containing human coagulation factors are responsive to HEMLIBRA but may overestimate the clinical hemostatic potential of HEMLIBRA. In contrast, assays containing bovine coagulation factors are insensitive to HEMLIBRA (no activity measured) and can be used to monitor endogenous or infused FVIII activity, or to measure anti-FVIII inhibitors.

HEMLIBRA remains active in the presence of inhibitors against FVIII, so it will produce a false-negative result in clotting-based Bethesda assays for functional inhibition of FVIII. Instead, a chromogenic Bethesda assay utilizing a bovine-based FVIII chromogenic test that is insensitive to HEMLIBRA may be used.

Due to the long half-life of HEMLIBRA, effects on coagulation assays may persist for up to 6 months after the last dose [see Clinical Pharmacology (12.3)].
This study is a randomized pilot study to test the acceptability and feasibility of a novel communication tool, called the CKM Jumpstart Tool, to promote discussion of CKM between patients with advanced CKM and their healthcare providers, the investigators hypothesize that the Guide will be feasible and acceptable to patients and their healthcare providers as reflected in greater discussion of CKM between them following use of the Tool as compared with usual care. The investigators will enroll 76 patients aged 75 years and older with advanced CKD and their healthcare providers from University of Washington Medicine and Veterans Affairs Puget Sound Health Care System. Patients will be randomized together in a 1:1 fashion to receive the intervention or usual care. Data from participants will be collected at the time of enrollment (T1), within 2-weeks of their following clinic visit with their healthcare provider (T2), and approximately 3-month after this clinic visit (T3). The primary outcome measure and measure of feasibility is difference in patient-reported rates of discussion of CKM with a healthcare provider at T2 and T3. The investigators will also evaluate whether provider document in the medical chart of patients whether they had a discussion about CKM with the patient at T2 and T3. The investigators will also collect attrition rates at T2 and T3 as a measure of acceptability. The investigators will further assess user experience of the CKM JumpStart by performing a qualitative analysis of post-intervention interviews with patients and nephrologists, coding for themes elucidating pros, cons and other considerations with using the CKM JumpStart Tool and discussion about CKM.
The invention discloses a blood-activating tincture, an acute filthy disease-extraction health method employing the blood-activating tincture and an acute filthy disease extractor, and belongs to the field of Chinese herbal medicines and health protection. The blood-activating tincture is prepared by soaking bone-joining elixir, ajuga taiwanensis, kusnezoff monkshood roots, asarum, artemisia rupestris, wild ginger, camphor and datura with alcohol. The acute filthy disease-extraction health method comprises the following steps: painting the blood-activating tincture on the affected part or between meridian points, extracting muscle to move by the acute filthy disease extractor, and repeating for a plurality of times, so that purple points appear on the muscle skin. The acute filthy disease extractor comprises a cylinder and a piston rod, wherein the piston rod can be pulled to extract muscle. The blood-activating tincture is capable of obviously relieving pain within a few minutes for rheumatic pain, muscle pain, joint pain, traumatic injuries, cervical-lumbar spine pain and the problems caused by cervical-lumbar spines. Self-actuated health protection can be carried out for slight discomfort by combining the blood-activating tincture with the acute filthy disease-extraction health method. Health treatment can be timely carried out for the diseases caused by five organism imbalance, and can be carried out without special medical workers; common emergencies can be obviously relieved; and death caused by emergencies of a stroke or cerebral infarction, myocardial infarction, vomiting and diarrhea, a stomachache and the like can be obviously reduced.
OBJECTIVE: In the hypothalamic-pituitary-gonadotrophin axis, estrogen plays a key role in the regulation of bone maturation and growth plate closure. This study was designed to explore the link between single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) gene with idiopathic short stature (ISS) susceptibility in a North Indian population.
METHODS: Four SNPs of ESR1 (rs543650, rs6557177, rs2234693 and rs9340799) were genotyped by Sanger sequencing in ISS patients and controls. Linkage disequilibrium (LD) and haplotyping were done by SNPStat and SHEsisPlus software. The extent of LD was determined by calculating D' and R2 values in SNP paired combinations.
RESULTS: Fifty-two ISS patients were compared with 68 controls. A significant positive association was found between rs6557177 and rs543650 genotype and ISS susceptibility. The frequencies of the rs6557177 CC genotype [p=0.030; odds ratio (OR)=0.13; 95% confidence interval (CI): 0.01-1.10] and rs543650 genotype TT (p=0.043; OR=0.29; 95% CI: 0.09-0.92) were increased in the ISS group compared with controls. However, no significant correlation was observed between clinical parameters of patients and these SNPs. rs543650 showed strong LD with rs2234693 and rs9340799, similarly rs2234693 and rs9340799.
CONCLUSION: Our study showed that the CC genotype at rs6557177 and TT genotype at rs543650 of ESR1 constituted a risk factor for developing ISS in North Indian children. These findings may lead to a better understanding of the SNPs associated with ISS susceptibility.
Group B was given hot pack at knee joint for 10-15min. Then they were asked to perform stretching and strengthening exercises of the knee with at least 10 repetitions in each set and a total two sets in a day.